Clinical Trial Update: Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigates Axitinib, a VEGF-pathway inhibitor, in patients with pheochromocytoma and paraganglioma; the study status is ACTIVE_NOT_RE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Axitinib (Inlyta) (Axitinib)

Snippet

Sponsor: Columbia University | Conditions: Pheochromocytoma, Paraganglioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING